CHIR-124

Catalog No.S2683 Batch:S268302

Print

Technical Data

Formula

C23H22ClN5O

Molecular Weight 419.91 CAS No. 405168-58-3
Solubility (25°C)* In vitro DMSO 7 mg/mL (16.67 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM in a cell-free assay. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.
Targets
Chk1 [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
GSK-3 [1]
(Cell-free assay)
0.3 nM 5.8 nM 6.6 nM 23.3 nM
In vitro CHIR-124 is a quinolone-based small molecule that is structurally unrelated to other known inhibitors of Chk1. CHIR-124 interacts synergistically with topoisomerase poisons (e.g., Camptothecin or SN-38) in causing growth inhibition in a variety of cancer cell lines, including breast carcinoma (MDA-MB-231 and MDA-MB-435) and colon carcinoma (SW-620 and Colo205), all of which contains the mutant p53 gene. CHIR-124 abrogates the SN-38-induced S and G2-M checkpoints and potentiates apoptosis in MDA-MD-435 breast cancer cells. The abrogation of the G2-Mcheckpoint and induction of apoptosis by CHIR-124 are enhanced by the loss of p53. [1] CHIR-124 also potently targets other kinases such as PDGFR and Flt3 with IC50 of 6.6 nM and 5.8 nM, respectively. [2]
In vivo CHIR-124 potentiates the growth inhibitory effects of Irinotecan by abrogating the G2-M checkpoint and increasing tumor apoptosis in an orthotopic breast cancer xenograft model.

Protocol (from reference)

Kinase Assay:[1]
  • Chk1 Assay

    For the Chk1 assay, the kinase domain is expressed in Sf9 insect cells, and a biotinylated cdc25c peptide containing the consensus Chk1/Chk2 phosphorylation site (*)(biotin-[AHX]SGSGS*GLYRSPSMP-ENLNRPR[CONH2]) is used as the substrate. A dilution series of CHIR-124 is mixed with a kinase reaction buffer containing a final concentration of 30 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 2 mM DTT, 4 mM EDTA, 25 mMβ-glycerophosphate, 5 mM MnCl2, 0.01% bovine serum albumin, 1.35 nM CHK1 kinase domain, 0.5 μM peptide substrate, and 1 AM unlabeled ATP, plus 5 nM 33Pγ-labeled ATP (specific activity = 2,000 Ci/mmol). Reactions and detection of the phosphate transfer are carried out by a radioactive method. Reactions are incubated at room temperature for 1 to 4 hours and the phosphorylated peptide captured on streptavidin-coated microtiter plates containing stop reaction buffer (25 mM EDTA [ethylenediaminetetraacetic acid], 50 mMHEPES, pH 7.5). Phosphorylated peptide is measured with the DELFIA TRF system using a Europium-labeled anti-phosphotyrosine antibody PT66. The concentration of CHIR-124 for IC50 is calculated using nonlinear regression with XL-Fit data analysis software.

Cell Assay:[1]
  • Cell lines

    MDA-MB-231, MDA-MB-435, SW-620, and COLO 205 cells

  • Concentrations

    0-2350 nM, dependent on cell types

  • Incubation Time

    48 hours

  • Method

    MDA-MB-231, MDA-MB-435, SW-620, and COLO 205 cells in log-phase are plated into 96-well microplates. CHIR-124 is serially diluted in the presence of six different concentrations of Camptothecin or 0 nM camptothecin. Camptothecin is also serially diluted in the absence of CHIR-124. CHIR-124 is added to cells in 96-well dishes and incubated at 37 °C for 48 hours. Each treatment condition is done in triplicate. Cell proliferation is monitored by the 3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), inner salt assay. MTS inner salt is added to the microplates, which are incubated for another 3 hours, and absorbance at 490 nm is read on a plate reader. The concentrations of each drug in the combinations required to produce 50% inhibition are plotted to generate the isoboles. Isobologram analysis of drug interaction is based the equation of Loewe additivity (1= D A /IC50, A + DB/IC50, B), where IC50, A and IC50, B are the concentrations of drugs to result in 50% inhibition for each drug alone, and DA and DB are concentrations of each drug in the combination that yield 50% overall inhibition. A diagonal line indicating Loewe additivity is included in each graph. Data points that fall below the line indicate synergy, whereas those that fall above the line will indicate antagonism

Animal Study:[1]
  • Animal Models

    MDA-MB-435 cells are implanted in the mammary fat pad of 8- to 10-week-old female immunodeficient mice.

  • Dosages

    10 mg/kg or 20 mg/kg

  • Administration

    CHIR-124 is given orally four times daily × 6 on days 2 to 7 in captisol.

Customer Product Validation

Data from [Oncotarget, 2014, 5(3), 667-78]

Data from [Data independently produced by , , J Pathol, 2015, 236: 348-359]

Data from [Data independently produced by , , J Virol, 2016, 90(20):9433-45]

Data from [Data independently produced by , , Transl Oncol, 2018, 11(1):140-146]

Selleck's CHIR-124 has been cited by 42 publications

p53-independent tumor suppression by cell-cycle arrest via CREB/ATF transcription factor OASIS [ Cell Rep, 2023, S2211-1247(23)00490-4] PubMed: 37178686
The MRN complex maintains the biliary-derived hepatocytes in liver regeneration through ATR-Chk1 pathway [ NPJ Regen Med, 2023, 8(1):20] PubMed: 37024481
The MRN complex maintains the biliary-derived hepatocytes in liver regeneration through ATR-Chk1 pathway [ npj Regenerative Medicine, 2023, 20-2023)] PubMed: None
Alternative Lengthening of Telomeres in Pediatric High-Grade Glioma and Therapeutic Implications [ Cancers (Basel), 2023, 15(12)3070] PubMed: 37370681
The Autonomous Parvovirus Minute Virus of Mice Localizes to Cellular Sites of DNA Damage Using ATR Signaling [ Viruses, 2023, 15(6)1243] PubMed: 37376543
ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe [ NAR Cancer, 2023, 5(1):zcac045] PubMed: 36644397
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies [ Blood, 2022, blood.2021014304] PubMed: 35704690
Syntaxin 18 regulates the DNA damage response and epithelial-to-mesenchymal transition to promote radiation resistance of lung cancer [ Cell Death Dis, 2022, 13(6):529] PubMed: 35668077
The SKP2-p27 axis defines susceptibility to cell death upon CHK1 inhibition [ Mol Oncol, 2022, 16(15):2771-2787] PubMed: 35673965
Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening [ Cancers (Basel), 2022, 14(6)1575] PubMed: 35326726

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.